nodes	percent_of_prediction	percent_of_DWPC	metapath
Tamoxifen—DHCR7—Epirubicin—testicular cancer	0.203	0.273	CbGbCtD
Tamoxifen—DHCR7—Doxorubicin—testicular cancer	0.108	0.145	CbGbCtD
Tamoxifen—ABCB11—Vinblastine—testicular cancer	0.0278	0.0374	CbGbCtD
Tamoxifen—CYP2A6—Ifosfamide—testicular cancer	0.0269	0.0362	CbGbCtD
Tamoxifen—ABCG2—Dactinomycin—testicular cancer	0.0211	0.0284	CbGbCtD
Tamoxifen—CYP3A7-CYP3A51P—Ifosfamide—testicular cancer	0.0184	0.0248	CbGbCtD
Tamoxifen—CYP3A7—Ifosfamide—testicular cancer	0.0184	0.0248	CbGbCtD
Tamoxifen—CYP2B6—Ifosfamide—testicular cancer	0.0175	0.0236	CbGbCtD
Tamoxifen—CYP1B1—Doxorubicin—testicular cancer	0.0171	0.023	CbGbCtD
Tamoxifen—ABCB11—Doxorubicin—testicular cancer	0.0171	0.023	CbGbCtD
Tamoxifen—ABCC2—Carboplatin—testicular cancer	0.0157	0.0211	CbGbCtD
Tamoxifen—ABCC2—Vinblastine—testicular cancer	0.0146	0.0197	CbGbCtD
Tamoxifen—ABCG2—Carboplatin—testicular cancer	0.0142	0.0191	CbGbCtD
Tamoxifen—CYP3A5—Ifosfamide—testicular cancer	0.0138	0.0186	CbGbCtD
Tamoxifen—ABCC2—Cisplatin—testicular cancer	0.0134	0.018	CbGbCtD
Tamoxifen—CYP2C8—Ifosfamide—testicular cancer	0.0133	0.0179	CbGbCtD
Tamoxifen—ABCC2—Etoposide—testicular cancer	0.0132	0.0177	CbGbCtD
Tamoxifen—ABCG2—Cisplatin—testicular cancer	0.0121	0.0163	CbGbCtD
Tamoxifen—ABCG2—Etoposide—testicular cancer	0.0119	0.016	CbGbCtD
Tamoxifen—CYP2C19—Ifosfamide—testicular cancer	0.0111	0.015	CbGbCtD
Tamoxifen—ESR2—seminiferous tubule of testis—testicular cancer	0.00947	0.124	CbGeAlD
Tamoxifen—CYP2C9—Ifosfamide—testicular cancer	0.00926	0.0125	CbGbCtD
Tamoxifen—ABCC2—Doxorubicin—testicular cancer	0.00899	0.0121	CbGbCtD
Tamoxifen—CYP19A1—corpus luteum—testicular cancer	0.00881	0.115	CbGeAlD
Tamoxifen—ABCC2—Methotrexate—testicular cancer	0.00871	0.0117	CbGbCtD
Tamoxifen—CYP2B6—Cisplatin—testicular cancer	0.00853	0.0115	CbGbCtD
Tamoxifen—CYP2E1—Etoposide—testicular cancer	0.00849	0.0114	CbGbCtD
Tamoxifen—ABCG2—Doxorubicin—testicular cancer	0.00813	0.0109	CbGbCtD
Tamoxifen—ABCG2—Methotrexate—testicular cancer	0.00787	0.0106	CbGbCtD
Tamoxifen—ABCB1—Dactinomycin—testicular cancer	0.00761	0.0102	CbGbCtD
Tamoxifen—CYP19A1—seminiferous tubule of testis—testicular cancer	0.00747	0.0973	CbGeAlD
Tamoxifen—CYP3A5—Etoposide—testicular cancer	0.0066	0.00888	CbGbCtD
Tamoxifen—CYP2C8—Etoposide—testicular cancer	0.00635	0.00854	CbGbCtD
Tamoxifen—CYP2B6—Doxorubicin—testicular cancer	0.00572	0.00769	CbGbCtD
Tamoxifen—CYP3A4—Ifosfamide—testicular cancer	0.00539	0.00725	CbGbCtD
Tamoxifen—CYP1A2—Etoposide—testicular cancer	0.00491	0.00661	CbGbCtD
Tamoxifen—ABCB1—Vinblastine—testicular cancer	0.00477	0.00642	CbGbCtD
Tamoxifen—CYP2C9—Cisplatin—testicular cancer	0.00451	0.00606	CbGbCtD
Tamoxifen—CYP2D6—Vinblastine—testicular cancer	0.00449	0.00604	CbGbCtD
Tamoxifen—ABCB1—Cisplatin—testicular cancer	0.00437	0.00588	CbGbCtD
Tamoxifen—ABCB1—Etoposide—testicular cancer	0.0043	0.00578	CbGbCtD
Tamoxifen—CYP19A1—semen—testicular cancer	0.00413	0.0538	CbGeAlD
Tamoxifen—ESR2—Ovarian Infertility Genes—DAZL—testicular cancer	0.00334	0.206	CbGpPWpGaD
Tamoxifen—ABCB1—Doxorubicin—testicular cancer	0.00293	0.00394	CbGbCtD
Tamoxifen—CYP3A4—Vinblastine—testicular cancer	0.00286	0.00384	CbGbCtD
Tamoxifen—ABCB1—Methotrexate—testicular cancer	0.00284	0.00382	CbGbCtD
Tamoxifen—CYP2D6—Doxorubicin—testicular cancer	0.00276	0.00371	CbGbCtD
Tamoxifen—SULT1A1—seminal vesicle—testicular cancer	0.00264	0.0344	CbGeAlD
Tamoxifen—CYP3A4—Etoposide—testicular cancer	0.00257	0.00346	CbGbCtD
Tamoxifen—EBPL—female gonad—testicular cancer	0.00195	0.0255	CbGeAlD
Tamoxifen—CYP19A1—Ovarian Infertility Genes—DAZL—testicular cancer	0.00188	0.116	CbGpPWpGaD
Tamoxifen—DHCR7—seminal vesicle—testicular cancer	0.00188	0.0245	CbGeAlD
Tamoxifen—ESRRA—seminal vesicle—testicular cancer	0.00185	0.0241	CbGeAlD
Tamoxifen—CYP3A4—Doxorubicin—testicular cancer	0.00176	0.00236	CbGbCtD
Tamoxifen—EBPL—testis—testicular cancer	0.00173	0.0226	CbGeAlD
Tamoxifen—SULT1A1—female gonad—testicular cancer	0.00155	0.0202	CbGeAlD
Tamoxifen—SULT1A1—testis—testicular cancer	0.00138	0.0179	CbGeAlD
Tamoxifen—DHCR7—gonad—testicular cancer	0.00136	0.0177	CbGeAlD
Tamoxifen—ESRRA—Preimplantation Embryo—DNMT3L—testicular cancer	0.0013	0.0801	CbGpPWpGaD
Tamoxifen—EBPL—lymph node—testicular cancer	0.00126	0.0164	CbGeAlD
Tamoxifen—CYP2A6—seminal vesicle—testicular cancer	0.00112	0.0145	CbGeAlD
Tamoxifen—DHCR7—female gonad—testicular cancer	0.0011	0.0144	CbGeAlD
Tamoxifen—FMO1—female gonad—testicular cancer	0.0011	0.0144	CbGeAlD
Tamoxifen—ESRRA—female gonad—testicular cancer	0.00109	0.0142	CbGeAlD
Tamoxifen—SULT1A1—lymph node—testicular cancer	0.000998	0.013	CbGeAlD
Tamoxifen—DHCR7—testis—testicular cancer	0.000979	0.0128	CbGeAlD
Tamoxifen—ESRRA—testis—testicular cancer	0.000964	0.0126	CbGeAlD
Tamoxifen—SIGMAR1—seminal vesicle—testicular cancer	0.00086	0.0112	CbGeAlD
Tamoxifen—ABCB11—testis—testicular cancer	0.000856	0.0112	CbGeAlD
Tamoxifen—FMO3—testis—testicular cancer	0.000846	0.011	CbGeAlD
Tamoxifen—ESR1—embryo—testicular cancer	0.00081	0.0106	CbGeAlD
Tamoxifen—ESR2—gonad—testicular cancer	0.000802	0.0105	CbGeAlD
Tamoxifen—CES1—female gonad—testicular cancer	0.000753	0.00982	CbGeAlD
Tamoxifen—DHCR7—lymph node—testicular cancer	0.00071	0.00925	CbGeAlD
Tamoxifen—FMO1—lymph node—testicular cancer	0.00071	0.00925	CbGeAlD
Tamoxifen—ESRRA—lymph node—testicular cancer	0.000699	0.00911	CbGeAlD
Tamoxifen—CES1—testis—testicular cancer	0.000668	0.00871	CbGeAlD
Tamoxifen—ESR2—female gonad—testicular cancer	0.000652	0.0085	CbGeAlD
Tamoxifen—CES1—NRF2 pathway—SLC2A6—testicular cancer	0.00065	0.04	CbGpPWpGaD
Tamoxifen—CYP19A1—gonad—testicular cancer	0.000632	0.00824	CbGeAlD
Tamoxifen—FMO3—lymph node—testicular cancer	0.000613	0.00799	CbGeAlD
Tamoxifen—ABCG2—seminal vesicle—testicular cancer	0.000609	0.00794	CbGeAlD
Tamoxifen—CYP1B1—gonad—testicular cancer	0.000591	0.00771	CbGeAlD
Tamoxifen—ESR2—testis—testicular cancer	0.000578	0.00754	CbGeAlD
Tamoxifen—SULT1A1—Phase II conjugation—HPGDS—testicular cancer	0.000578	0.0356	CbGpPWpGaD
Tamoxifen—ESR1—gonad—testicular cancer	0.00055	0.00716	CbGeAlD
Tamoxifen—UGT1A4—NRF2 pathway—SLC2A6—testicular cancer	0.000528	0.0325	CbGpPWpGaD
Tamoxifen—CYP2E1—seminal vesicle—testicular cancer	0.000527	0.00688	CbGeAlD
Tamoxifen—CYP19A1—female gonad—testicular cancer	0.000514	0.0067	CbGeAlD
Tamoxifen—SIGMAR1—female gonad—testicular cancer	0.000505	0.00659	CbGeAlD
Tamoxifen—CES1—lymph node—testicular cancer	0.000484	0.00631	CbGeAlD
Tamoxifen—CYP1B1—female gonad—testicular cancer	0.00048	0.00626	CbGeAlD
Tamoxifen—CYP19A1—testis—testicular cancer	0.000456	0.00594	CbGeAlD
Tamoxifen—SIGMAR1—testis—testicular cancer	0.000448	0.00584	CbGeAlD
Tamoxifen—ESR1—female gonad—testicular cancer	0.000447	0.00582	CbGeAlD
Tamoxifen—ABCC2—testis—testicular cancer	0.000435	0.00567	CbGeAlD
Tamoxifen—CYP1B1—testis—testicular cancer	0.000426	0.00555	CbGeAlD
Tamoxifen—ESR2—lymph node—testicular cancer	0.000419	0.00547	CbGeAlD
Tamoxifen—CYP2B6—gonad—testicular cancer	0.000406	0.00529	CbGeAlD
Tamoxifen—ESR1—testis—testicular cancer	0.000396	0.00516	CbGeAlD
Tamoxifen—ABCG2—female gonad—testicular cancer	0.000358	0.00466	CbGeAlD
Tamoxifen—CYP1A1—female gonad—testicular cancer	0.00034	0.00443	CbGeAlD
Tamoxifen—SULT1A1—Biological oxidations—HPGDS—testicular cancer	0.000338	0.0208	CbGpPWpGaD
Tamoxifen—CYP3A5—female gonad—testicular cancer	0.000332	0.00433	CbGeAlD
Tamoxifen—CYP19A1—lymph node—testicular cancer	0.00033	0.00431	CbGeAlD
Tamoxifen—CYP2C8—testis—testicular cancer	0.000326	0.00425	CbGeAlD
Tamoxifen—SIGMAR1—lymph node—testicular cancer	0.000325	0.00423	CbGeAlD
Tamoxifen—ABCB1—embryo—testicular cancer	0.00032	0.00417	CbGeAlD
Tamoxifen—ABCG2—testis—testicular cancer	0.000317	0.00414	CbGeAlD
Tamoxifen—ABCC2—lymph node—testicular cancer	0.000315	0.00411	CbGeAlD
Tamoxifen—CYP1B1—lymph node—testicular cancer	0.000309	0.00403	CbGeAlD
Tamoxifen—ABCB1—seminal vesicle—testicular cancer	0.0003	0.00392	CbGeAlD
Tamoxifen—ABCC2—NRF2 pathway—SLC2A6—testicular cancer	0.000296	0.0182	CbGpPWpGaD
Tamoxifen—CYP2B6—testis—testicular cancer	0.000293	0.00382	CbGeAlD
Tamoxifen—UGT1A4—Phase II conjugation—HPGDS—testicular cancer	0.000287	0.0177	CbGpPWpGaD
Tamoxifen—ESR1—lymph node—testicular cancer	0.000287	0.00374	CbGeAlD
Tamoxifen—FMO1—Biological oxidations—HPGDS—testicular cancer	0.000281	0.0173	CbGpPWpGaD
Tamoxifen—CYP2E1—testis—testicular cancer	0.000275	0.00358	CbGeAlD
Tamoxifen—CYP1B1—Aryl Hydrocarbon Receptor—HPGDS—testicular cancer	0.000259	0.0159	CbGpPWpGaD
Tamoxifen—CYP2D6—female gonad—testicular cancer	0.000245	0.0032	CbGeAlD
Tamoxifen—CYP1B1—Arachidonic acid metabolism—HPGDS—testicular cancer	0.000242	0.0149	CbGpPWpGaD
Tamoxifen—ESR1—Aryl Hydrocarbon Receptor—HPGDS—testicular cancer	0.00024	0.0148	CbGpPWpGaD
Tamoxifen—CYP2A6—NRF2 pathway—SLC2A6—testicular cancer	0.000234	0.0144	CbGpPWpGaD
Tamoxifen—ABCG2—lymph node—testicular cancer	0.00023	0.003	CbGeAlD
Tamoxifen—CYP1A1—lymph node—testicular cancer	0.000218	0.00285	CbGeAlD
Tamoxifen—CYP2D6—testis—testicular cancer	0.000218	0.00284	CbGeAlD
Tamoxifen—ABCB1—gonad—testicular cancer	0.000217	0.00283	CbGeAlD
Tamoxifen—ESR2—Plasma membrane estrogen receptor signaling—MMP2—testicular cancer	0.000213	0.0131	CbGpPWpGaD
Tamoxifen—FMO3—Biological oxidations—HPGDS—testicular cancer	0.000201	0.0124	CbGpPWpGaD
Tamoxifen—ESR1—LKB1 signaling events—STK11—testicular cancer	0.000184	0.0114	CbGpPWpGaD
Tamoxifen—ABCB1—female gonad—testicular cancer	0.000176	0.0023	CbGeAlD
Tamoxifen—UGT1A4—Biological oxidations—HPGDS—testicular cancer	0.000168	0.0104	CbGpPWpGaD
Tamoxifen—CYP1A1—Aryl Hydrocarbon Receptor—HPGDS—testicular cancer	0.000159	0.00981	CbGpPWpGaD
Tamoxifen—ABCB1—testis—testicular cancer	0.000156	0.00204	CbGeAlD
Tamoxifen—ESR2—Integrated Pancreatic Cancer Pathway—HPGDS—testicular cancer	0.000153	0.0094	CbGpPWpGaD
Tamoxifen—CYP1A1—Arachidonic acid metabolism—HPGDS—testicular cancer	0.000149	0.00918	CbGpPWpGaD
Tamoxifen—CYP2C8—Arachidonic acid metabolism—HPGDS—testicular cancer	0.000137	0.00842	CbGpPWpGaD
Tamoxifen—DHCR7—Metabolism of lipids and lipoproteins—HPGDS—testicular cancer	0.000132	0.00814	CbGpPWpGaD
Tamoxifen—EBP—Metabolism of lipids and lipoproteins—HPGDS—testicular cancer	0.000125	0.00772	CbGpPWpGaD
Tamoxifen—CYP2C19—Arachidonic acid metabolism—HPGDS—testicular cancer	0.000122	0.00751	CbGpPWpGaD
Tamoxifen—Aspartate aminotransferase increased—Epirubicin—testicular cancer	0.000121	0.000742	CcSEcCtD
Tamoxifen—Hypersensitivity—Dactinomycin—testicular cancer	0.00012	0.000735	CcSEcCtD
Tamoxifen—ESRRA—Gene Expression—DNMT3L—testicular cancer	0.00012	0.00738	CbGpPWpGaD
Tamoxifen—Abdominal discomfort—Methotrexate—testicular cancer	0.000119	0.000729	CcSEcCtD
Tamoxifen—Alanine aminotransferase increased—Epirubicin—testicular cancer	0.000119	0.000726	CcSEcCtD
Tamoxifen—Urticaria—Ifosfamide—testicular cancer	0.000119	0.000726	CcSEcCtD
Tamoxifen—Abdominal pain—Ifosfamide—testicular cancer	0.000118	0.000723	CcSEcCtD
Tamoxifen—Pancytopenia—Methotrexate—testicular cancer	0.000118	0.000722	CcSEcCtD
Tamoxifen—Mood swings—Doxorubicin—testicular cancer	0.000118	0.000722	CcSEcCtD
Tamoxifen—Musculoskeletal discomfort—Cisplatin—testicular cancer	0.000118	0.000718	CcSEcCtD
Tamoxifen—Infection—Etoposide—testicular cancer	0.000117	0.000717	CcSEcCtD
Tamoxifen—Asthenia—Dactinomycin—testicular cancer	0.000117	0.000716	CcSEcCtD
Tamoxifen—Blood creatinine increased—Doxorubicin—testicular cancer	0.000117	0.000714	CcSEcCtD
Tamoxifen—Dysphagia—Epirubicin—testicular cancer	0.000117	0.000712	CcSEcCtD
Tamoxifen—Influenza—Epirubicin—testicular cancer	0.000117	0.000712	CcSEcCtD
Tamoxifen—Neutropenia—Methotrexate—testicular cancer	0.000116	0.000711	CcSEcCtD
Tamoxifen—Paraesthesia—Cisplatin—testicular cancer	0.000116	0.000708	CcSEcCtD
Tamoxifen—Thrombocytopenia—Etoposide—testicular cancer	0.000116	0.000707	CcSEcCtD
Tamoxifen—Liver function test abnormal—Doxorubicin—testicular cancer	0.000115	0.000704	CcSEcCtD
Tamoxifen—Dyspnoea—Cisplatin—testicular cancer	0.000115	0.000703	CcSEcCtD
Tamoxifen—Erectile dysfunction—Methotrexate—testicular cancer	0.000115	0.000701	CcSEcCtD
Tamoxifen—Hyperhidrosis—Etoposide—testicular cancer	0.000114	0.000698	CcSEcCtD
Tamoxifen—Pancreatitis—Epirubicin—testicular cancer	0.000114	0.000698	CcSEcCtD
Tamoxifen—Angina pectoris—Epirubicin—testicular cancer	0.000114	0.000693	CcSEcCtD
Tamoxifen—ABCB1—lymph node—testicular cancer	0.000113	0.00148	CbGeAlD
Tamoxifen—Anorexia—Etoposide—testicular cancer	0.000113	0.000688	CcSEcCtD
Tamoxifen—Aspartate aminotransferase increased—Doxorubicin—testicular cancer	0.000112	0.000686	CcSEcCtD
Tamoxifen—Decreased appetite—Cisplatin—testicular cancer	0.000112	0.000685	CcSEcCtD
Tamoxifen—Bronchitis—Epirubicin—testicular cancer	0.000112	0.000685	CcSEcCtD
Tamoxifen—Diarrhoea—Dactinomycin—testicular cancer	0.000112	0.000683	CcSEcCtD
Tamoxifen—Pneumonia—Methotrexate—testicular cancer	0.000112	0.000682	CcSEcCtD
Tamoxifen—Gastrointestinal disorder—Cisplatin—testicular cancer	0.000111	0.000681	CcSEcCtD
Tamoxifen—Vomiting—Bleomycin—testicular cancer	0.000111	0.00068	CcSEcCtD
Tamoxifen—CYP2C9—Arachidonic acid metabolism—HPGDS—testicular cancer	0.000111	0.00685	CbGpPWpGaD
Tamoxifen—ESR2—Integrated Pancreatic Cancer Pathway—STK11—testicular cancer	0.000111	0.00683	CbGpPWpGaD
Tamoxifen—Depression—Methotrexate—testicular cancer	0.000111	0.000676	CcSEcCtD
Tamoxifen—Pancytopenia—Epirubicin—testicular cancer	0.000111	0.000676	CcSEcCtD
Tamoxifen—Rash—Bleomycin—testicular cancer	0.00011	0.000675	CcSEcCtD
Tamoxifen—Pain—Cisplatin—testicular cancer	0.00011	0.000674	CcSEcCtD
Tamoxifen—Dermatitis—Bleomycin—testicular cancer	0.00011	0.000674	CcSEcCtD
Tamoxifen—Hypersensitivity—Ifosfamide—testicular cancer	0.00011	0.000674	CcSEcCtD
Tamoxifen—Stevens-Johnson syndrome—Methotrexate—testicular cancer	0.00011	0.000672	CcSEcCtD
Tamoxifen—Alanine aminotransferase increased—Doxorubicin—testicular cancer	0.00011	0.000672	CcSEcCtD
Tamoxifen—Neutropenia—Epirubicin—testicular cancer	0.000109	0.000666	CcSEcCtD
Tamoxifen—Dysphagia—Doxorubicin—testicular cancer	0.000108	0.000659	CcSEcCtD
Tamoxifen—Influenza—Doxorubicin—testicular cancer	0.000108	0.000659	CcSEcCtD
Tamoxifen—Asthenia—Ifosfamide—testicular cancer	0.000107	0.000656	CcSEcCtD
Tamoxifen—ESR1—Plasma membrane estrogen receptor signaling—MMP2—testicular cancer	0.000107	0.0066	CbGpPWpGaD
Tamoxifen—Sweating—Methotrexate—testicular cancer	0.000106	0.00065	CcSEcCtD
Tamoxifen—Paraesthesia—Etoposide—testicular cancer	0.000106	0.000648	CcSEcCtD
Tamoxifen—Weight increased—Epirubicin—testicular cancer	0.000106	0.000648	CcSEcCtD
Tamoxifen—Pruritus—Ifosfamide—testicular cancer	0.000106	0.000647	CcSEcCtD
Tamoxifen—Pancreatitis—Doxorubicin—testicular cancer	0.000106	0.000646	CcSEcCtD
Tamoxifen—Weight decreased—Epirubicin—testicular cancer	0.000105	0.000644	CcSEcCtD
Tamoxifen—Dyspnoea—Etoposide—testicular cancer	0.000105	0.000644	CcSEcCtD
Tamoxifen—ESR1—FOXM1 transcription factor network—MMP2—testicular cancer	0.000105	0.00648	CbGpPWpGaD
Tamoxifen—Angina pectoris—Doxorubicin—testicular cancer	0.000105	0.000642	CcSEcCtD
Tamoxifen—Pneumonia—Epirubicin—testicular cancer	0.000105	0.000638	CcSEcCtD
Tamoxifen—Nausea—Bleomycin—testicular cancer	0.000104	0.000635	CcSEcCtD
Tamoxifen—Vomiting—Dactinomycin—testicular cancer	0.000104	0.000634	CcSEcCtD
Tamoxifen—Bronchitis—Doxorubicin—testicular cancer	0.000104	0.000633	CcSEcCtD
Tamoxifen—Stevens-Johnson syndrome—Epirubicin—testicular cancer	0.000103	0.000629	CcSEcCtD
Tamoxifen—Rash—Dactinomycin—testicular cancer	0.000103	0.000629	CcSEcCtD
Tamoxifen—Decreased appetite—Etoposide—testicular cancer	0.000103	0.000628	CcSEcCtD
Tamoxifen—ABCG2—Imatinib Resistance in Chronic Myeloid Leukemia—KIT—testicular cancer	0.000103	0.00632	CbGpPWpGaD
Tamoxifen—Diarrhoea—Ifosfamide—testicular cancer	0.000102	0.000626	CcSEcCtD
Tamoxifen—Pancytopenia—Doxorubicin—testicular cancer	0.000102	0.000625	CcSEcCtD
Tamoxifen—Gastrointestinal disorder—Etoposide—testicular cancer	0.000102	0.000623	CcSEcCtD
Tamoxifen—Fatigue—Etoposide—testicular cancer	0.000102	0.000623	CcSEcCtD
Tamoxifen—CYP1A2—Aryl Hydrocarbon Receptor—HPGDS—testicular cancer	0.000102	0.00626	CbGpPWpGaD
Tamoxifen—Pain—Etoposide—testicular cancer	0.000101	0.000618	CcSEcCtD
Tamoxifen—Constipation—Etoposide—testicular cancer	0.000101	0.000618	CcSEcCtD
Tamoxifen—Urinary tract infection—Epirubicin—testicular cancer	0.000101	0.000617	CcSEcCtD
Tamoxifen—Neutropenia—Doxorubicin—testicular cancer	0.000101	0.000616	CcSEcCtD
Tamoxifen—Haemoglobin—Methotrexate—testicular cancer	0.0001	0.000612	CcSEcCtD
Tamoxifen—ESRRA—Metabolism of lipids and lipoproteins—HPGDS—testicular cancer	0.0001	0.00617	CbGpPWpGaD
Tamoxifen—Haemorrhage—Methotrexate—testicular cancer	9.97e-05	0.000609	CcSEcCtD
Tamoxifen—Hepatitis—Methotrexate—testicular cancer	9.97e-05	0.000609	CcSEcCtD
Tamoxifen—Sweating—Epirubicin—testicular cancer	9.97e-05	0.000608	CcSEcCtD
Tamoxifen—Dizziness—Ifosfamide—testicular cancer	9.9e-05	0.000605	CcSEcCtD
Tamoxifen—Pharyngitis—Methotrexate—testicular cancer	9.9e-05	0.000604	CcSEcCtD
Tamoxifen—Weight increased—Doxorubicin—testicular cancer	9.82e-05	0.000599	CcSEcCtD
Tamoxifen—Weight decreased—Doxorubicin—testicular cancer	9.76e-05	0.000596	CcSEcCtD
Tamoxifen—Sinusitis—Epirubicin—testicular cancer	9.75e-05	0.000595	CcSEcCtD
Tamoxifen—Nausea—Dactinomycin—testicular cancer	9.71e-05	0.000593	CcSEcCtD
Tamoxifen—Pneumonia—Doxorubicin—testicular cancer	9.67e-05	0.000591	CcSEcCtD
Tamoxifen—Gastrointestinal pain—Etoposide—testicular cancer	9.67e-05	0.00059	CcSEcCtD
Tamoxifen—Visual impairment—Methotrexate—testicular cancer	9.61e-05	0.000587	CcSEcCtD
Tamoxifen—Stevens-Johnson syndrome—Doxorubicin—testicular cancer	9.54e-05	0.000582	CcSEcCtD
Tamoxifen—Vomiting—Ifosfamide—testicular cancer	9.52e-05	0.000581	CcSEcCtD
Tamoxifen—Hypersensitivity—Cisplatin—testicular cancer	9.51e-05	0.000581	CcSEcCtD
Tamoxifen—CYP1A2—Arachidonic acid metabolism—HPGDS—testicular cancer	9.5e-05	0.00585	CbGpPWpGaD
Tamoxifen—ABCC2—Transmembrane transport of small molecules—SLC2A6—testicular cancer	9.48e-05	0.00584	CbGpPWpGaD
Tamoxifen—Rash—Ifosfamide—testicular cancer	9.44e-05	0.000576	CcSEcCtD
Tamoxifen—Dermatitis—Ifosfamide—testicular cancer	9.43e-05	0.000576	CcSEcCtD
Tamoxifen—Erythema multiforme—Methotrexate—testicular cancer	9.43e-05	0.000576	CcSEcCtD
Tamoxifen—Urticaria—Etoposide—testicular cancer	9.4e-05	0.000574	CcSEcCtD
Tamoxifen—Haemoglobin—Epirubicin—testicular cancer	9.38e-05	0.000573	CcSEcCtD
Tamoxifen—CYP19A1—Biological oxidations—HPGDS—testicular cancer	9.35e-05	0.00576	CbGpPWpGaD
Tamoxifen—Abdominal pain—Etoposide—testicular cancer	9.35e-05	0.000571	CcSEcCtD
Tamoxifen—Urinary tract infection—Doxorubicin—testicular cancer	9.35e-05	0.000571	CcSEcCtD
Tamoxifen—Hepatitis—Epirubicin—testicular cancer	9.33e-05	0.00057	CcSEcCtD
Tamoxifen—Haemorrhage—Epirubicin—testicular cancer	9.33e-05	0.00057	CcSEcCtD
Tamoxifen—Hypoaesthesia—Epirubicin—testicular cancer	9.28e-05	0.000567	CcSEcCtD
Tamoxifen—Asthenia—Cisplatin—testicular cancer	9.26e-05	0.000566	CcSEcCtD
Tamoxifen—Pharyngitis—Epirubicin—testicular cancer	9.26e-05	0.000565	CcSEcCtD
Tamoxifen—Sweating—Doxorubicin—testicular cancer	9.22e-05	0.000563	CcSEcCtD
Tamoxifen—Oedema peripheral—Epirubicin—testicular cancer	9.19e-05	0.000561	CcSEcCtD
Tamoxifen—Sinusitis—Doxorubicin—testicular cancer	9.02e-05	0.000551	CcSEcCtD
Tamoxifen—CYP1B1—Biological oxidations—HPGDS—testicular cancer	9e-05	0.00555	CbGpPWpGaD
Tamoxifen—Visual impairment—Epirubicin—testicular cancer	8.99e-05	0.000549	CcSEcCtD
Tamoxifen—Nausea—Ifosfamide—testicular cancer	8.89e-05	0.000543	CcSEcCtD
Tamoxifen—Diarrhoea—Cisplatin—testicular cancer	8.83e-05	0.000539	CcSEcCtD
Tamoxifen—Erythema multiforme—Epirubicin—testicular cancer	8.82e-05	0.000539	CcSEcCtD
Tamoxifen—Alopecia—Methotrexate—testicular cancer	8.81e-05	0.000538	CcSEcCtD
Tamoxifen—Hypersensitivity—Etoposide—testicular cancer	8.71e-05	0.000532	CcSEcCtD
Tamoxifen—Erythema—Methotrexate—testicular cancer	8.68e-05	0.00053	CcSEcCtD
Tamoxifen—Haemoglobin—Doxorubicin—testicular cancer	8.68e-05	0.00053	CcSEcCtD
Tamoxifen—Flushing—Epirubicin—testicular cancer	8.66e-05	0.000529	CcSEcCtD
Tamoxifen—Haemorrhage—Doxorubicin—testicular cancer	8.63e-05	0.000527	CcSEcCtD
Tamoxifen—Hepatitis—Doxorubicin—testicular cancer	8.63e-05	0.000527	CcSEcCtD
Tamoxifen—Hypoaesthesia—Doxorubicin—testicular cancer	8.59e-05	0.000525	CcSEcCtD
Tamoxifen—Pharyngitis—Doxorubicin—testicular cancer	8.57e-05	0.000523	CcSEcCtD
Tamoxifen—Oedema peripheral—Doxorubicin—testicular cancer	8.51e-05	0.000519	CcSEcCtD
Tamoxifen—Dysgeusia—Methotrexate—testicular cancer	8.5e-05	0.000519	CcSEcCtD
Tamoxifen—Asthenia—Etoposide—testicular cancer	8.49e-05	0.000518	CcSEcCtD
Tamoxifen—Back pain—Methotrexate—testicular cancer	8.4e-05	0.000513	CcSEcCtD
Tamoxifen—Pruritus—Etoposide—testicular cancer	8.37e-05	0.000511	CcSEcCtD
Tamoxifen—Arrhythmia—Epirubicin—testicular cancer	8.34e-05	0.000509	CcSEcCtD
Tamoxifen—Visual impairment—Doxorubicin—testicular cancer	8.32e-05	0.000508	CcSEcCtD
Tamoxifen—Alopecia—Epirubicin—testicular cancer	8.25e-05	0.000503	CcSEcCtD
Tamoxifen—ABCG2—Transmembrane transport of small molecules—SLC2A6—testicular cancer	8.24e-05	0.00508	CbGpPWpGaD
Tamoxifen—Vomiting—Cisplatin—testicular cancer	8.21e-05	0.000501	CcSEcCtD
Tamoxifen—Erythema multiforme—Doxorubicin—testicular cancer	8.16e-05	0.000498	CcSEcCtD
Tamoxifen—Rash—Cisplatin—testicular cancer	8.14e-05	0.000497	CcSEcCtD
Tamoxifen—Dermatitis—Cisplatin—testicular cancer	8.13e-05	0.000497	CcSEcCtD
Tamoxifen—Erythema—Epirubicin—testicular cancer	8.12e-05	0.000496	CcSEcCtD
Tamoxifen—CYP3A7—Biological oxidations—HPGDS—testicular cancer	8.12e-05	0.005	CbGpPWpGaD
Tamoxifen—Diarrhoea—Etoposide—testicular cancer	8.09e-05	0.000494	CcSEcCtD
Tamoxifen—Anaemia—Methotrexate—testicular cancer	8.02e-05	0.00049	CcSEcCtD
Tamoxifen—Flushing—Doxorubicin—testicular cancer	8.01e-05	0.000489	CcSEcCtD
Tamoxifen—ESR1—ATF-2 transcription factor network—MMP2—testicular cancer	8.01e-05	0.00493	CbGpPWpGaD
Tamoxifen—Dysgeusia—Epirubicin—testicular cancer	7.95e-05	0.000486	CcSEcCtD
Tamoxifen—Back pain—Epirubicin—testicular cancer	7.86e-05	0.00048	CcSEcCtD
Tamoxifen—Dizziness—Etoposide—testicular cancer	7.82e-05	0.000478	CcSEcCtD
Tamoxifen—Muscle spasms—Epirubicin—testicular cancer	7.81e-05	0.000477	CcSEcCtD
Tamoxifen—Leukopenia—Methotrexate—testicular cancer	7.77e-05	0.000474	CcSEcCtD
Tamoxifen—Arrhythmia—Doxorubicin—testicular cancer	7.71e-05	0.000471	CcSEcCtD
Tamoxifen—ESR1—Integrated Pancreatic Cancer Pathway—HPGDS—testicular cancer	7.7e-05	0.00474	CbGpPWpGaD
Tamoxifen—Nausea—Cisplatin—testicular cancer	7.67e-05	0.000468	CcSEcCtD
Tamoxifen—Alopecia—Doxorubicin—testicular cancer	7.63e-05	0.000466	CcSEcCtD
Tamoxifen—ESR2—Gene Expression—DNMT3L—testicular cancer	7.62e-05	0.0047	CbGpPWpGaD
Tamoxifen—Cough—Methotrexate—testicular cancer	7.57e-05	0.000462	CcSEcCtD
Tamoxifen—CYP19A1—Integrated Breast Cancer Pathway—STK11—testicular cancer	7.54e-05	0.00465	CbGpPWpGaD
Tamoxifen—Vomiting—Etoposide—testicular cancer	7.52e-05	0.000459	CcSEcCtD
Tamoxifen—Erythema—Doxorubicin—testicular cancer	7.52e-05	0.000459	CcSEcCtD
Tamoxifen—Anaemia—Epirubicin—testicular cancer	7.51e-05	0.000458	CcSEcCtD
Tamoxifen—Rash—Etoposide—testicular cancer	7.46e-05	0.000455	CcSEcCtD
Tamoxifen—Dermatitis—Etoposide—testicular cancer	7.45e-05	0.000455	CcSEcCtD
Tamoxifen—CYP2A6—Biological oxidations—HPGDS—testicular cancer	7.44e-05	0.00459	CbGpPWpGaD
Tamoxifen—Headache—Etoposide—testicular cancer	7.41e-05	0.000452	CcSEcCtD
Tamoxifen—Chest pain—Methotrexate—testicular cancer	7.39e-05	0.000451	CcSEcCtD
Tamoxifen—Arthralgia—Methotrexate—testicular cancer	7.39e-05	0.000451	CcSEcCtD
Tamoxifen—Myalgia—Methotrexate—testicular cancer	7.39e-05	0.000451	CcSEcCtD
Tamoxifen—Dysgeusia—Doxorubicin—testicular cancer	7.36e-05	0.000449	CcSEcCtD
Tamoxifen—Discomfort—Methotrexate—testicular cancer	7.3e-05	0.000446	CcSEcCtD
Tamoxifen—Leukopenia—Epirubicin—testicular cancer	7.27e-05	0.000444	CcSEcCtD
Tamoxifen—Back pain—Doxorubicin—testicular cancer	7.27e-05	0.000444	CcSEcCtD
Tamoxifen—Muscle spasms—Doxorubicin—testicular cancer	7.23e-05	0.000441	CcSEcCtD
Tamoxifen—Cough—Epirubicin—testicular cancer	7.09e-05	0.000433	CcSEcCtD
Tamoxifen—Infection—Methotrexate—testicular cancer	7.04e-05	0.00043	CcSEcCtD
Tamoxifen—Nausea—Etoposide—testicular cancer	7.03e-05	0.000429	CcSEcCtD
Tamoxifen—Hypertension—Epirubicin—testicular cancer	7.01e-05	0.000428	CcSEcCtD
Tamoxifen—Anaemia—Doxorubicin—testicular cancer	6.95e-05	0.000424	CcSEcCtD
Tamoxifen—Thrombocytopenia—Methotrexate—testicular cancer	6.94e-05	0.000424	CcSEcCtD
Tamoxifen—Myalgia—Epirubicin—testicular cancer	6.92e-05	0.000422	CcSEcCtD
Tamoxifen—Arthralgia—Epirubicin—testicular cancer	6.92e-05	0.000422	CcSEcCtD
Tamoxifen—Chest pain—Epirubicin—testicular cancer	6.92e-05	0.000422	CcSEcCtD
Tamoxifen—Anxiety—Epirubicin—testicular cancer	6.89e-05	0.000421	CcSEcCtD
Tamoxifen—Hyperhidrosis—Methotrexate—testicular cancer	6.85e-05	0.000418	CcSEcCtD
Tamoxifen—Discomfort—Epirubicin—testicular cancer	6.83e-05	0.000417	CcSEcCtD
Tamoxifen—Dry mouth—Epirubicin—testicular cancer	6.76e-05	0.000413	CcSEcCtD
Tamoxifen—Anorexia—Methotrexate—testicular cancer	6.75e-05	0.000412	CcSEcCtD
Tamoxifen—ESR1—Integrated Breast Cancer Pathway—STK11—testicular cancer	6.75e-05	0.00416	CbGpPWpGaD
Tamoxifen—Leukopenia—Doxorubicin—testicular cancer	6.73e-05	0.000411	CcSEcCtD
Tamoxifen—Oedema—Epirubicin—testicular cancer	6.63e-05	0.000405	CcSEcCtD
Tamoxifen—Infection—Epirubicin—testicular cancer	6.59e-05	0.000402	CcSEcCtD
Tamoxifen—Cough—Doxorubicin—testicular cancer	6.56e-05	0.0004	CcSEcCtD
Tamoxifen—Thrombocytopenia—Epirubicin—testicular cancer	6.49e-05	0.000396	CcSEcCtD
Tamoxifen—Hypertension—Doxorubicin—testicular cancer	6.49e-05	0.000396	CcSEcCtD
Tamoxifen—Musculoskeletal discomfort—Methotrexate—testicular cancer	6.45e-05	0.000394	CcSEcCtD
Tamoxifen—Hyperhidrosis—Epirubicin—testicular cancer	6.41e-05	0.000391	CcSEcCtD
Tamoxifen—Insomnia—Methotrexate—testicular cancer	6.41e-05	0.000391	CcSEcCtD
Tamoxifen—Chest pain—Doxorubicin—testicular cancer	6.4e-05	0.000391	CcSEcCtD
Tamoxifen—Arthralgia—Doxorubicin—testicular cancer	6.4e-05	0.000391	CcSEcCtD
Tamoxifen—Myalgia—Doxorubicin—testicular cancer	6.4e-05	0.000391	CcSEcCtD
Tamoxifen—Anxiety—Doxorubicin—testicular cancer	6.38e-05	0.000389	CcSEcCtD
Tamoxifen—Paraesthesia—Methotrexate—testicular cancer	6.36e-05	0.000388	CcSEcCtD
Tamoxifen—Discomfort—Doxorubicin—testicular cancer	6.32e-05	0.000386	CcSEcCtD
Tamoxifen—Anorexia—Epirubicin—testicular cancer	6.32e-05	0.000386	CcSEcCtD
Tamoxifen—Dyspnoea—Methotrexate—testicular cancer	6.32e-05	0.000386	CcSEcCtD
Tamoxifen—Dry mouth—Doxorubicin—testicular cancer	6.26e-05	0.000382	CcSEcCtD
Tamoxifen—Dyspepsia—Methotrexate—testicular cancer	6.24e-05	0.000381	CcSEcCtD
Tamoxifen—ESR1—Signaling by ERBB4—KITLG—testicular cancer	6.21e-05	0.00383	CbGpPWpGaD
Tamoxifen—Decreased appetite—Methotrexate—testicular cancer	6.16e-05	0.000376	CcSEcCtD
Tamoxifen—Oedema—Doxorubicin—testicular cancer	6.13e-05	0.000375	CcSEcCtD
Tamoxifen—Gastrointestinal disorder—Methotrexate—testicular cancer	6.12e-05	0.000373	CcSEcCtD
Tamoxifen—Fatigue—Methotrexate—testicular cancer	6.11e-05	0.000373	CcSEcCtD
Tamoxifen—Infection—Doxorubicin—testicular cancer	6.09e-05	0.000372	CcSEcCtD
Tamoxifen—Pain—Methotrexate—testicular cancer	6.06e-05	0.00037	CcSEcCtD
Tamoxifen—CYP1A2—Phase II conjugation—HPGDS—testicular cancer	6.04e-05	0.00372	CbGpPWpGaD
Tamoxifen—Musculoskeletal discomfort—Epirubicin—testicular cancer	6.04e-05	0.000369	CcSEcCtD
Tamoxifen—Thrombocytopenia—Doxorubicin—testicular cancer	6.01e-05	0.000367	CcSEcCtD
Tamoxifen—CYP2B6—Biological oxidations—HPGDS—testicular cancer	6e-05	0.0037	CbGpPWpGaD
Tamoxifen—Insomnia—Epirubicin—testicular cancer	6e-05	0.000366	CcSEcCtD
Tamoxifen—Paraesthesia—Epirubicin—testicular cancer	5.95e-05	0.000363	CcSEcCtD
Tamoxifen—Hyperhidrosis—Doxorubicin—testicular cancer	5.93e-05	0.000362	CcSEcCtD
Tamoxifen—Dyspnoea—Epirubicin—testicular cancer	5.91e-05	0.000361	CcSEcCtD
Tamoxifen—DHCR7—Metabolism—HPGDS—testicular cancer	5.89e-05	0.00363	CbGpPWpGaD
Tamoxifen—CYP2E1—Biological oxidations—HPGDS—testicular cancer	5.88e-05	0.00362	CbGpPWpGaD
Tamoxifen—CYP3A5—Biological oxidations—HPGDS—testicular cancer	5.87e-05	0.00362	CbGpPWpGaD
Tamoxifen—Anorexia—Doxorubicin—testicular cancer	5.85e-05	0.000357	CcSEcCtD
Tamoxifen—Dyspepsia—Epirubicin—testicular cancer	5.84e-05	0.000356	CcSEcCtD
Tamoxifen—Gastrointestinal pain—Methotrexate—testicular cancer	5.79e-05	0.000354	CcSEcCtD
Tamoxifen—SULT1A1—Metabolism—HPGDS—testicular cancer	5.78e-05	0.00356	CbGpPWpGaD
Tamoxifen—Decreased appetite—Epirubicin—testicular cancer	5.76e-05	0.000352	CcSEcCtD
Tamoxifen—Gastrointestinal disorder—Epirubicin—testicular cancer	5.72e-05	0.000349	CcSEcCtD
Tamoxifen—Fatigue—Epirubicin—testicular cancer	5.72e-05	0.000349	CcSEcCtD
Tamoxifen—Constipation—Epirubicin—testicular cancer	5.67e-05	0.000346	CcSEcCtD
Tamoxifen—Pain—Epirubicin—testicular cancer	5.67e-05	0.000346	CcSEcCtD
Tamoxifen—Urticaria—Methotrexate—testicular cancer	5.63e-05	0.000344	CcSEcCtD
Tamoxifen—Abdominal pain—Methotrexate—testicular cancer	5.6e-05	0.000342	CcSEcCtD
Tamoxifen—ESR1—Integrated Pancreatic Cancer Pathway—STK11—testicular cancer	5.59e-05	0.00345	CbGpPWpGaD
Tamoxifen—Musculoskeletal discomfort—Doxorubicin—testicular cancer	5.59e-05	0.000341	CcSEcCtD
Tamoxifen—EBP—Metabolism—HPGDS—testicular cancer	5.58e-05	0.00344	CbGpPWpGaD
Tamoxifen—Insomnia—Doxorubicin—testicular cancer	5.55e-05	0.000339	CcSEcCtD
Tamoxifen—ABCB1—Imatinib Resistance in Chronic Myeloid Leukemia—KIT—testicular cancer	5.55e-05	0.00342	CbGpPWpGaD
Tamoxifen—CYP1A1—Biological oxidations—HPGDS—testicular cancer	5.54e-05	0.00342	CbGpPWpGaD
Tamoxifen—Paraesthesia—Doxorubicin—testicular cancer	5.51e-05	0.000336	CcSEcCtD
Tamoxifen—Dyspnoea—Doxorubicin—testicular cancer	5.47e-05	0.000334	CcSEcCtD
Tamoxifen—Gastrointestinal pain—Epirubicin—testicular cancer	5.42e-05	0.000331	CcSEcCtD
Tamoxifen—Dyspepsia—Doxorubicin—testicular cancer	5.4e-05	0.00033	CcSEcCtD
Tamoxifen—Decreased appetite—Doxorubicin—testicular cancer	5.33e-05	0.000326	CcSEcCtD
Tamoxifen—Gastrointestinal disorder—Doxorubicin—testicular cancer	5.3e-05	0.000323	CcSEcCtD
Tamoxifen—Fatigue—Doxorubicin—testicular cancer	5.29e-05	0.000323	CcSEcCtD
Tamoxifen—Urticaria—Epirubicin—testicular cancer	5.27e-05	0.000322	CcSEcCtD
Tamoxifen—Constipation—Doxorubicin—testicular cancer	5.25e-05	0.00032	CcSEcCtD
Tamoxifen—Pain—Doxorubicin—testicular cancer	5.25e-05	0.00032	CcSEcCtD
Tamoxifen—Abdominal pain—Epirubicin—testicular cancer	5.24e-05	0.00032	CcSEcCtD
Tamoxifen—Hypersensitivity—Methotrexate—testicular cancer	5.22e-05	0.000319	CcSEcCtD
Tamoxifen—CYP2C8—Biological oxidations—HPGDS—testicular cancer	5.08e-05	0.00313	CbGpPWpGaD
Tamoxifen—Asthenia—Methotrexate—testicular cancer	5.08e-05	0.00031	CcSEcCtD
Tamoxifen—Gastrointestinal pain—Doxorubicin—testicular cancer	5.02e-05	0.000306	CcSEcCtD
Tamoxifen—Pruritus—Methotrexate—testicular cancer	5.01e-05	0.000306	CcSEcCtD
Tamoxifen—Hypersensitivity—Epirubicin—testicular cancer	4.88e-05	0.000298	CcSEcCtD
Tamoxifen—Urticaria—Doxorubicin—testicular cancer	4.87e-05	0.000298	CcSEcCtD
Tamoxifen—Abdominal pain—Doxorubicin—testicular cancer	4.85e-05	0.000296	CcSEcCtD
Tamoxifen—Diarrhoea—Methotrexate—testicular cancer	4.85e-05	0.000296	CcSEcCtD
Tamoxifen—FMO1—Metabolism—HPGDS—testicular cancer	4.8e-05	0.00296	CbGpPWpGaD
Tamoxifen—ABCB11—Metabolism of lipids and lipoproteins—HPGDS—testicular cancer	4.76e-05	0.00293	CbGpPWpGaD
Tamoxifen—Asthenia—Epirubicin—testicular cancer	4.76e-05	0.00029	CcSEcCtD
Tamoxifen—Pruritus—Epirubicin—testicular cancer	4.69e-05	0.000286	CcSEcCtD
Tamoxifen—Dizziness—Methotrexate—testicular cancer	4.68e-05	0.000286	CcSEcCtD
Tamoxifen—ESR1—Signaling by ERBB4—FGFR3—testicular cancer	4.62e-05	0.00284	CbGpPWpGaD
Tamoxifen—CYP2C19—Biological oxidations—HPGDS—testicular cancer	4.54e-05	0.0028	CbGpPWpGaD
Tamoxifen—Diarrhoea—Epirubicin—testicular cancer	4.54e-05	0.000277	CcSEcCtD
Tamoxifen—Hypersensitivity—Doxorubicin—testicular cancer	4.52e-05	0.000276	CcSEcCtD
Tamoxifen—Vomiting—Methotrexate—testicular cancer	4.5e-05	0.000275	CcSEcCtD
Tamoxifen—Rash—Methotrexate—testicular cancer	4.47e-05	0.000273	CcSEcCtD
Tamoxifen—Dermatitis—Methotrexate—testicular cancer	4.46e-05	0.000272	CcSEcCtD
Tamoxifen—ESRRA—Metabolism—HPGDS—testicular cancer	4.46e-05	0.00275	CbGpPWpGaD
Tamoxifen—ABCB1—Transmembrane transport of small molecules—SLC2A6—testicular cancer	4.46e-05	0.00274	CbGpPWpGaD
Tamoxifen—Headache—Methotrexate—testicular cancer	4.44e-05	0.000271	CcSEcCtD
Tamoxifen—Asthenia—Doxorubicin—testicular cancer	4.4e-05	0.000269	CcSEcCtD
Tamoxifen—Dizziness—Epirubicin—testicular cancer	4.38e-05	0.000268	CcSEcCtD
Tamoxifen—Pruritus—Doxorubicin—testicular cancer	4.34e-05	0.000265	CcSEcCtD
Tamoxifen—DHCR7—Metabolism—STK11—testicular cancer	4.28e-05	0.00263	CbGpPWpGaD
Tamoxifen—ESR1—Signaling by ERBB4—KIT—testicular cancer	4.24e-05	0.00261	CbGpPWpGaD
Tamoxifen—Vomiting—Epirubicin—testicular cancer	4.22e-05	0.000257	CcSEcCtD
Tamoxifen—Nausea—Methotrexate—testicular cancer	4.21e-05	0.000257	CcSEcCtD
Tamoxifen—SULT1A1—Metabolism—STK11—testicular cancer	4.2e-05	0.00259	CbGpPWpGaD
Tamoxifen—Diarrhoea—Doxorubicin—testicular cancer	4.2e-05	0.000256	CcSEcCtD
Tamoxifen—ESRRA—Gene Expression—H2AFZ—testicular cancer	4.19e-05	0.00258	CbGpPWpGaD
Tamoxifen—Rash—Epirubicin—testicular cancer	4.18e-05	0.000255	CcSEcCtD
Tamoxifen—Dermatitis—Epirubicin—testicular cancer	4.18e-05	0.000255	CcSEcCtD
Tamoxifen—CYP2D6—Biological oxidations—HPGDS—testicular cancer	4.17e-05	0.00257	CbGpPWpGaD
Tamoxifen—Headache—Epirubicin—testicular cancer	4.15e-05	0.000254	CcSEcCtD
Tamoxifen—CYP2C9—Biological oxidations—HPGDS—testicular cancer	4.14e-05	0.00255	CbGpPWpGaD
Tamoxifen—ABCB1—Integrated Pancreatic Cancer Pathway—HPGDS—testicular cancer	4.07e-05	0.00251	CbGpPWpGaD
Tamoxifen—Dizziness—Doxorubicin—testicular cancer	4.06e-05	0.000248	CcSEcCtD
Tamoxifen—EBP—Metabolism—STK11—testicular cancer	4.05e-05	0.0025	CbGpPWpGaD
Tamoxifen—Nausea—Epirubicin—testicular cancer	3.94e-05	0.00024	CcSEcCtD
Tamoxifen—Vomiting—Doxorubicin—testicular cancer	3.9e-05	0.000238	CcSEcCtD
Tamoxifen—Rash—Doxorubicin—testicular cancer	3.87e-05	0.000236	CcSEcCtD
Tamoxifen—Dermatitis—Doxorubicin—testicular cancer	3.86e-05	0.000236	CcSEcCtD
Tamoxifen—ESR1—Gene Expression—DNMT3L—testicular cancer	3.84e-05	0.00237	CbGpPWpGaD
Tamoxifen—Headache—Doxorubicin—testicular cancer	3.84e-05	0.000235	CcSEcCtD
Tamoxifen—Nausea—Doxorubicin—testicular cancer	3.64e-05	0.000222	CcSEcCtD
Tamoxifen—CYP19A1—Metabolism of lipids and lipoproteins—HPGDS—testicular cancer	3.59e-05	0.00221	CbGpPWpGaD
Tamoxifen—CYP1A2—Biological oxidations—HPGDS—testicular cancer	3.54e-05	0.00218	CbGpPWpGaD
Tamoxifen—FMO1—Metabolism—STK11—testicular cancer	3.49e-05	0.00215	CbGpPWpGaD
Tamoxifen—CYP1B1—Metabolism of lipids and lipoproteins—HPGDS—testicular cancer	3.46e-05	0.00213	CbGpPWpGaD
Tamoxifen—FMO3—Metabolism—HPGDS—testicular cancer	3.43e-05	0.00211	CbGpPWpGaD
Tamoxifen—ESRRA—Metabolism—STK11—testicular cancer	3.24e-05	0.002	CbGpPWpGaD
Tamoxifen—ABCB1—Integrated Pancreatic Cancer Pathway—STK11—testicular cancer	2.96e-05	0.00182	CbGpPWpGaD
Tamoxifen—UGT1A4—Metabolism—HPGDS—testicular cancer	2.87e-05	0.00177	CbGpPWpGaD
Tamoxifen—ESR1—Signaling Pathways—INSL3—testicular cancer	2.73e-05	0.00168	CbGpPWpGaD
Tamoxifen—CYP3A4—Biological oxidations—HPGDS—testicular cancer	2.73e-05	0.00168	CbGpPWpGaD
Tamoxifen—ESR2—Gene Expression—H2AFZ—testicular cancer	2.67e-05	0.00164	CbGpPWpGaD
Tamoxifen—FMO3—Metabolism—STK11—testicular cancer	2.49e-05	0.00154	CbGpPWpGaD
Tamoxifen—CYP1A1—Metabolism of lipids and lipoproteins—HPGDS—testicular cancer	2.13e-05	0.00131	CbGpPWpGaD
Tamoxifen—ABCB11—Metabolism—HPGDS—testicular cancer	2.12e-05	0.00131	CbGpPWpGaD
Tamoxifen—UGT1A4—Metabolism—STK11—testicular cancer	2.09e-05	0.00129	CbGpPWpGaD
Tamoxifen—CYP2C8—Metabolism of lipids and lipoproteins—HPGDS—testicular cancer	1.95e-05	0.0012	CbGpPWpGaD
Tamoxifen—CYP2C19—Metabolism of lipids and lipoproteins—HPGDS—testicular cancer	1.74e-05	0.00107	CbGpPWpGaD
Tamoxifen—CYP19A1—Metabolism—HPGDS—testicular cancer	1.6e-05	0.000985	CbGpPWpGaD
Tamoxifen—CYP2C9—Metabolism of lipids and lipoproteins—HPGDS—testicular cancer	1.59e-05	0.000979	CbGpPWpGaD
Tamoxifen—CYP1B1—Metabolism—HPGDS—testicular cancer	1.54e-05	0.000949	CbGpPWpGaD
Tamoxifen—ABCB11—Metabolism—STK11—testicular cancer	1.54e-05	0.000949	CbGpPWpGaD
Tamoxifen—ABCG2—Metabolism—HPGDS—testicular cancer	1.4e-05	0.000863	CbGpPWpGaD
Tamoxifen—CYP3A7—Metabolism—HPGDS—testicular cancer	1.39e-05	0.000855	CbGpPWpGaD
Tamoxifen—CYP1A2—Metabolism of lipids and lipoproteins—HPGDS—testicular cancer	1.36e-05	0.000836	CbGpPWpGaD
Tamoxifen—ESR1—Gene Expression—H2AFZ—testicular cancer	1.35e-05	0.000829	CbGpPWpGaD
Tamoxifen—CYP2A6—Metabolism—HPGDS—testicular cancer	1.27e-05	0.000784	CbGpPWpGaD
Tamoxifen—CYP19A1—Metabolism—STK11—testicular cancer	1.16e-05	0.000716	CbGpPWpGaD
Tamoxifen—CYP1B1—Metabolism—STK11—testicular cancer	1.12e-05	0.000689	CbGpPWpGaD
Tamoxifen—CYP2B6—Metabolism—HPGDS—testicular cancer	1.03e-05	0.000633	CbGpPWpGaD
Tamoxifen—ABCG2—Metabolism—STK11—testicular cancer	1.02e-05	0.000627	CbGpPWpGaD
Tamoxifen—CYP3A7—Metabolism—STK11—testicular cancer	1.01e-05	0.000622	CbGpPWpGaD
Tamoxifen—CYP2E1—Metabolism—HPGDS—testicular cancer	1.01e-05	0.00062	CbGpPWpGaD
Tamoxifen—CYP3A5—Metabolism—HPGDS—testicular cancer	1e-05	0.000618	CbGpPWpGaD
Tamoxifen—CYP1A1—Metabolism—HPGDS—testicular cancer	9.48e-06	0.000584	CbGpPWpGaD
Tamoxifen—CYP2A6—Metabolism—STK11—testicular cancer	9.25e-06	0.00057	CbGpPWpGaD
Tamoxifen—ESR1—Signaling Pathways—H2AFZ—testicular cancer	8.75e-06	0.000539	CbGpPWpGaD
Tamoxifen—ESR1—Signaling Pathways—STK11—testicular cancer	8.7e-06	0.000536	CbGpPWpGaD
Tamoxifen—CYP2C8—Metabolism—HPGDS—testicular cancer	8.69e-06	0.000536	CbGpPWpGaD
Tamoxifen—ESR1—Signaling Pathways—KITLG—testicular cancer	8.05e-06	0.000496	CbGpPWpGaD
Tamoxifen—CYP2C19—Metabolism—HPGDS—testicular cancer	7.76e-06	0.000478	CbGpPWpGaD
Tamoxifen—ABCB1—Metabolism—HPGDS—testicular cancer	7.57e-06	0.000467	CbGpPWpGaD
Tamoxifen—CYP2B6—Metabolism—STK11—testicular cancer	7.46e-06	0.00046	CbGpPWpGaD
Tamoxifen—CYP2E1—Metabolism—STK11—testicular cancer	7.31e-06	0.00045	CbGpPWpGaD
Tamoxifen—CYP3A5—Metabolism—STK11—testicular cancer	7.29e-06	0.000449	CbGpPWpGaD
Tamoxifen—CYP2D6—Metabolism—HPGDS—testicular cancer	7.14e-06	0.00044	CbGpPWpGaD
Tamoxifen—CYP2C9—Metabolism—HPGDS—testicular cancer	7.08e-06	0.000436	CbGpPWpGaD
Tamoxifen—CYP1A1—Metabolism—STK11—testicular cancer	6.89e-06	0.000424	CbGpPWpGaD
Tamoxifen—CYP2C8—Metabolism—STK11—testicular cancer	6.32e-06	0.000389	CbGpPWpGaD
Tamoxifen—CYP1A2—Metabolism—HPGDS—testicular cancer	6.05e-06	0.000373	CbGpPWpGaD
Tamoxifen—ESR1—Signaling Pathways—FGFR3—testicular cancer	5.98e-06	0.000368	CbGpPWpGaD
Tamoxifen—CYP2C19—Metabolism—STK11—testicular cancer	5.64e-06	0.000347	CbGpPWpGaD
Tamoxifen—ABCB1—Metabolism—STK11—testicular cancer	5.5e-06	0.000339	CbGpPWpGaD
Tamoxifen—ESR1—Signaling Pathways—KIT—testicular cancer	5.49e-06	0.000338	CbGpPWpGaD
Tamoxifen—CYP2D6—Metabolism—STK11—testicular cancer	5.19e-06	0.000319	CbGpPWpGaD
Tamoxifen—CYP2C9—Metabolism—STK11—testicular cancer	5.14e-06	0.000317	CbGpPWpGaD
Tamoxifen—CYP3A4—Metabolism—HPGDS—testicular cancer	4.67e-06	0.000287	CbGpPWpGaD
Tamoxifen—CYP1A2—Metabolism—STK11—testicular cancer	4.39e-06	0.000271	CbGpPWpGaD
Tamoxifen—CYP3A4—Metabolism—STK11—testicular cancer	3.39e-06	0.000209	CbGpPWpGaD
